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Objective: To ev a lu a te  se ria l m e a su re m e n ts  o f sa liv a ry  es­
tr io l (E3) to  d e tec t in c re ased  r isk  o f sp o n ta n e o u s  p re te rm  
la b o r  a n d  p re te rm  b ir th .
Methods: A  m ask ed , p ro sp e c tiv e , m u ltic e n te r  tr ia l o f 956 
w o m e n  w ith  s in g le to n  p re g n an c ie s  w a s  c o m p le te d  a t e ig h t 
U n ite d  S ta te s  m ed ica l cen ters . S a liv a  w a s  co llec ted  w e ek ly , 
b e g in n in g  a t th e  22 n d  w e e k  o f g e s ta tio n  u n til  b ir th ,  and  
te s te d  fo r  u n c o n ju g a te d  E3 b y  e n z y m e -lin k e d  im m u n o so r­
b e n t  assay . W o m en  w ere  se p a ra te d  in to  h ig h -r isk  a n d  low - 
r isk  g ro u p s  u s in g  th e  C re asy  sco rin g  system .
Results: A  s in g le , p o s itiv e  (at o r  ab o v e  2.1 ng/m L ) sa liv a ry  
E3 te s t  p re d ic te d  an  in c re a sed  r isk  o f sp o n ta n e o u s  p re te rm  
la b o r  a n d  d e liv e ry  in  th e  to ta l p o p u la t io n  (re la tiv e  r isk  [R R ] 
4.0, P  <  .005), in  th e  lo w -r isk  p o p u la tio n  (RR 4.0, P  S  .05), 
a n d  in  th e  h ig h -r isk  p o p u la tio n  (RR 3.4, P  =  .05). T w o 
co n secu tiv e  p o sitiv e  te s ts  s ig n ific a n tly  in c re a sed  th e  R R  in 
all s tu d y  g ro u p s , w ith  a d ra m a tic  im p ro v e m e n t in  tes t 
sp ec ific ity  a n d  p o sitiv e  p re d ic tiv e  v a lu e  b u t  o n ly  a m o d es t 
decrease  in  se n s it iv ity . In  w o m e n  w h o  p re se n te d  w ith  sy m p ­
to m a tic  p re te rm  lab o r , sa liv a ry  E3 id en tif ie d  61%  of th o se  
w h o  d e liv e re d  w ith in  2 w e ek s , u s in g  a th re s h o ld  o f 1.4 
ng/m L .
Conclusion: E lev a ted  sa liv a ry  E3 is a sso c ia ted  w ith  in ­
creased  risk  o f p re te rm  b ir th  in  a sy m p to m a tic  w o m e n  a n d  
sy m p to m a tic  w o m e n  w h o  p re se n t fo r  e v a lu a tio n  o f p re te rm  
lab o r. (O b s te t G y n eco l 2000;96;490-7. © 2000 b y  T h e  A m er­
ican  C o llege  o f O b s te tr ic ian s  a n d  G y n eco log ists.)
Recent data show that 11% of women in the United 
States deliver before completing 37 weeks' gestation.1 
Sequelae of biologic immaturity at birth can persist for 
life and can engender immense direct and indirect costs.
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U niversity o f  M ichigan, A n n  Arbor, M ichigan, the U niversity o f  
California, San Francisco, California, and the U niversity o f Utah, Salt 
Lake C ity, Utah.
Efforts to prevent preterm birth have failed largely 
because of the heterogeneous nature of the condition 
and our inability to define which women would benefit 
from specific treatments. Interventions are most likely 
to be effective if pathophysiologic processes of preterm 
parturition can be identified and specifically remedied.
Biochemical markers directly linked to biologic mech­
anisms of parturition are needed so etiologic-based 
interventions can be tested. Because placental estrogens 
are important in mammalian parturition, their potential 
as biomarkers of impending term, preterm, or post-term 
labor and delivery has been explored.2-6 Of the three 
major placental estrogens, estriol (E3), estradiol (E2), 
and estrone (E1), E3 is the most abundant during late 
pregnancy.2,7-9 In humans, over 90% of E3 is derived 
from fetal and placental sources.10 Maternal serum E3 is 
first detectable at 9 weeks' gestation.2,7,11 Serum E3 
levels increase gradually during the first and second 
trimesters. More rapid increases occur during the third 
trimester, with a characteristic surge preceding the 
onset of labor by several weeks.12 The increase in E3 has 
been shown by direct measurement or by an increase in 
salivary E3: progesterone ratio. This increase occurs 
approximately 3 to 4 weeks before the onset of parturi­
tion, in term, preterm, and post-term pregnancies.12-14 
Additionally, women with prolonged pregnancies who 
showed increases in salivary E3 were more likely to 
deliver spontaneously than women who did not have 
E3 increases.15
Saliva is a useful matrix for measuring E3 steroid 
hormones because the unbound, unconjugated (free, 
biologically active) fraction of E3 in saliva correlates
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with free serum concentrations. We determined the 
feasibility of salivary E3 in detecting increased risk of 
preterm labor.16 In that study, subjects typically had a 
surge or increase of salivary E3 approximately 3 weeks 
before parturition, regardless of whether delivery was 
preterm, term, or post-term. Using those data, a receiver 
operating characteristic (ROC) curve was constructed, 
and a salivary E3 level at or above 2.1 ng/m L predicted 
preterm labor more accurately than traditional risk 
assessment methods.16
In the current study we prospectively examined 
weekly saliva samples in women with singleton preg­
nancies at eight tertiary care sites in the United States to 
determine the utility of salivary E3 for identifying 
women at increased risk for preterm birth.
Materials and Methods
We conducted a prospective, longitudinal, masked, 
multicenter study to observe pregnant women from 
enrollment to delivery. It was approved by the research 
review board at each institution. Subjects gave in­
formed written consent in English or Spanish. The trial 
was conducted between May 1995 and December 1996 
at the antenatal clinics of eight United States medical 
centers. Neither care providers nor subjects had access 
to test results, and laboratory personnel were masked to 
clinical information.
Subjects were instructed to collect unstimulated sa­
liva between 9 a m  and 8 pm  because no significant 
variation in E3 levels has been found between those 
hours.17 Each subject was asked to rinse her mouth with 
water, wait 10 minutes, then drool 2 mL of saliva into 
the plastic tube that was provided. Subjects were asked 
to avoid eating, drinking, smoking, tooth brushing, 
mouth washing, or gum chewing for 1 hour before 
collection.
Prior unpublished data showed no difference in 
mailed samples and those collected in clinic and frozen 
promptly. Samples collected at home were sent in 
mailers to the clinic, where they were stored ( 20C). 
Samples were kept frozen at 20C until all subjects 
delivered. Samples were masked and randomized by 
computer-generated random number list at each study 
center, then mailed to Biex, Inc. (Dublin, CA), for batch 
assaying. Randomization of samples was done before 
mailing to guarantee masking of laboratory personnel. 
Samples were tested for unconjugated (free) E3 using a 
described competitive microplate enzyme immunoas­
say (SalEst; Biex, Inc., Dublin, CA).16 Salivary E3 at least
2.1 ng/m L was designated as positive.
For study purposes, preterm labor and delivery were 
defined as spontaneous preterm labor with intact mem­
branes that resulted in preterm birth within 72 hours
and before 37 completed weeks' gestation, respectively. 
Symptomatic preterm labor was defined as presentation 
to labor and delivery for evaluation of symptoms con­
sistent with preterm labor. Gestational age was deter­
mined by last menstrual period (LMP), ultrasound 
examination(s), obstetric assessment, and examination 
of the neonate. If there was more than a 14-day differ­
ence between the age determined by LMP and ultra­
sound, the earliest ultrasound measurement and exam­
ination of the neonate were used to assign gestational 
age at birth. Gestational age determinations were made 
before test specimens were processed. Women with 
singleton pregnancies were considered eligible if their 
pregnancies were between 21 and 25 weeks' gestation, 
they were at least 18 years of age, and gave informed 
consent. Exclusion criteria included symptoms of pre­
term labor; tocolytic therapy; placenta previa; cervical 
changes requiring cerclage; ruptured membranes in the 
current pregnancy; preeclampsia; medications known 
to affect hormone levels (eg, Dilantin, Haldol); planned 
cesarean delivery; presence of major congenital abnor­
malities, fetal growth restriction, erythroblastosis fe­
talis, or fetal death; an oral condition that would inter­
fere with saliva collection; a maternal medical 
complication that requires specialized obstetric care (eg, 
chronic hypertension, renal failure, or any other serious 
medical condition); or history of drug or ethanol abuse.
Risk status for preterm labor was designated by the 
Creasy score: a score of at least 10 was considered 
high-risk and below 10 was considered low-risk.1 Sub­
jects were enrolled at 21-25 weeks' gestation and ob­
served at weekly intervals until delivery. A  baseline 
examination including assessment for signs and symp­
toms of preterm labor (abdominal pain, backache, flu­
like symptoms, pelvic pressure, cramping, change in 
vaginal discharge, vaginal bleeding, diarrhea); evalua­
tion for contractions or rupture of membranes; and a 
digital vaginal examination to assess the position, con­
sistency, length, and dilatation of the cervix was com­
pleted at enrollment. Demographic and obstetric infor­
mation, including details of prior pregnancies and the 
current pregnancy, was obtained from patients' medical 
records. Subsequent clinic visits included questioning 
of subjects for signs or symptoms of preterm labor and 
performing a cervical examination every 4 weeks begin­
ning at week 27, with recording of changes in medica­
tion, hospitalization, emergency department visits, and 
appreciation of uterine contractions. Inquiries intended 
to ensure that home saliva samples were collected and 
submitted properly were made at each visit.
In the event of hospitalization or outpatient evalua­
tion for signs and symptoms of preterm labor or pre­
term rupture of membranes (PROM), saliva collection 
was continued, and data on symptoms of preterm labor
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(abdominal pain, cramping, backache, flu-like symp­
toms, pelvic pressure, change in vaginal discharge, 
vaginal bleeding, contractions, and treatments), were 
recorded. Delivery and neonatal data were collected 
from hospital records.
Subjects were withdrawn from the study if they did 
not supply saliva samples for 3 consecutive weeks or 
did not attend two consecutive clinic visits (unless 
hospitalized and supplying weekly saliva samples). 
Women who received betamethasone or dexametha- 
sone to induce fetal lung maturation were not included 
in the primary analysis because of known suppression 
of salivary E3 by corticosteroids.19 The effects of toco- 
lytics on salivary E3 are not known; therefore, those 
women also were excluded from analysis. Women with 
PROM and preterm births caused by obstetric indica­
tions were also excluded from primary analysis. 
Women who had preterm labor and term births also 
were excluded. These exclusions ensured focused eval­
uation of serial salivary E3 measurement for detecting 
women at risk for preterm birth.
We also evaluated the ability of salivary E3 to deter­
mine the risk of preterm birth within 2 weeks of 
admission in women admitted with signs and symp­
toms of preterm labor. Patients who had salivary E3 
tests available within 2 weeks before admission and in 
whom delivery outcome was known were eligible for 
this separate analysis. Women subsequently treated 
with betamethasone or tocolytics were not excluded 
from analysis in this symptomatic group.
A  power analysis was done to determine the sample 
required to detect a difference in the incidence of 
preterm labor and delivery between women with a 
salivary E3 level of at least 2.1 ng/m L and those with 
salivary E3 less than 2.1 ng/mL. Based on results of a 
previous study, a sample of 150 high-risk women and 
110 low-risk women was estimated assuming a two­
tailed significance level of .05, a power of 80%, and the 
ability to detect a difference of 5-20% for an effect size of 
approximately 0.5. This sample was based on preterm 
birth prevalence of 18% for high-risk and 19% for 
low-risk groups in our previous study, and we assumed 
that there would be 12 spontaneous preterm births in 
each group. The high background prevalence of pre­
term birth in the low-risk group and the exclusion 
criteria for betamethasone and tocolytic use made us 
decide to enroll women until approximately 12 evalu­
able preterm births were available for analysis in both 
groups.
Data for the primary endpoint, difference in incidence 
of preterm labor followed by preterm delivery (before 
37 weeks) between women with salivary E3 at least 2.1 
ng/m L and those with salivary E3 less than 2.1 ng/mL, 
were analyzed using Fisher exact test (two-tailed), with
alpha at 0.05. Relative risks (RRs) and 95% confidence 
intervals (CIs) were calculated. The high- and low-risk 
groups were combined and evaluated using the Mantel- 
Haenszel test and Woolf test. The Woolf test was 
used with the Mantel-Haenszel to test the heterogeneity 
of the odds ratio (OR) between low- and high-risk 
studies. An insignificant finding suggests that intra­
study results were equivalent; therefore, results from 
the combined analysis can be taken at face value. 
Center-to-center variation was assessed with a three- 
factor (gestational age, clinical center, preterm delivery) 
repeated measures analysis of variance with repeated 
analysis on the maximum intrapatient salivary E3 value 
collected during each gestational week. To avoid equiv­
ocal definitions of preterm labor, the primary analysis 
compared salivary E3 findings for subjects with preterm 
labor and delivery with those of subjects who delivered 
at term without preterm labor. Survival curves were 
constructed using data from all evaluable subjects to 
determine time to delivery after a single positive test at 
varying gestational ages using Kaplan-Meier estimates 
of survival. Survival curves were compared by log-rank 
test.
We also evaluated the utility of salivary E3 for 
predicting delivery intervals in women who presented 
with symptoms of preterm labor. Absolute levels in 
women who delivered within 2 weeks of presentation 
were compared with those who delivered after 2 weeks 
by Student t test. Receiver operating characteristic 
curves were generated to determine optimal salivary E3 
value that determined risk of preterm birth within 2 
weeks. Descriptive statistics were calculated on the 
value with the optimal combination of sensitivity and 
specificity.
Results
We enrolled 956 pregnant women, 302 (31.6%) of whom 
were designated high risk and 654 (68.4%) as low risk. 
Demographic characteristics of eligible women at base­
line were similar among test centers with respect to age 
distribution, prepregnancy weight, obesity, weight at 
enrollment, height, number of children, gravidity, num­
ber of abortions, and number of preterm and term 
pregnancies. Most women were 20-35 years old (78%), 
weighed over 100 pounds (92%), were married or living 
with a mate (67%), had not had other preterm pregnan­
cies (81%), had not had abortions (53%), and had at least 
one child (59%). Most (83.0%) high-risk women had one 
risk factor worth 10 points (eg, premature delivery, 
uterine anomaly, second-trimester abortion). Demo­
graphic characteristics of women who were salivary 
E3-positive versus negative are presented in Table 1. 
No differences were noted between groups. The dispo-
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T ab le  1. Demographic Characteristics of Subjects With High 
and Low Salivary Estriol Levels
Salivary E3 
>2.1 ng/m L 
(n = 187)
Salivary E3
<2.1 ng/m L  Combined 
(n = 769) (n = 956)
Age (y) 27.3 26.1 26.4
Race (%)
White 49.7 61.6 59.3
Black 13.4 18.1 17.2
Asian 5.3 4.4 4.6
Hispanic 26.2 13.0 15.6
Other 5.4 2.9 3.3
Prepregnancy weight 142.9 148.5 147.4
(lbs)
Weight at enrollment 155.6 164.8 163.0
(lbs)
Education (y) (%)
12 49.7 48.4 48.6
12- 16 38.5 37.7 37.9
16 9.1 9.5 9.4
Not reported 2.7 4.4 4.1
Marital status (%)
Single 26.2 30.4 29.6
Married 54.0 51.6 52.0
Live-in partner 17.7 14.4 15.1
Divorced or 2.1 3.6 3.4
separated 
Gravida (%)
1 24.1 23.8 23.9
1 75.9 76.2 76.1
Abortions (%)
0 56.7 51.6 52.6
1 26.2 29.4 28.8
2 8.0 11.8 11.1
3 8.0 6.2 6.6
Not reported 1.1 1.0 0.9
Prior preterm births (%)
0 82.4 80.7 81.1
1 14.4 13.8 13.9
2 2.6 4.5 4.2
Not reported 0.5 1.0 0.8
E3 estriol.
P = not significant for all comparisons.
sition of all subjects is shown in Figure 1. There was no 
center-to-center variation in salivary E3 results.
Numbers of enrolled and analyzed subjects and sub­
jects excluded from analysis of primary endpoints are 
shown in Table 2. No demographic differences were 
statistically significant between analyzed and excluded 
subjects. Noncompliance was the most common reason 
for discontinuation from the study (147 of 242), fol­
lowed by development of exclusion criteria after enroll­
ment (49 of 242), fetal death (four of 242), and those lost 
to follow-up (42 of 242). Seven hundred fourteen 
women were initially eligible for the primary analysis. 
We excluded 113 of them because of the reasons listed 
in Table 2. Primary analysis was done on two groups 
(n =  601), preterm labor followed by preterm delivery,
Figure 1. Outcomes of study subjects.
and term deliveries. Among 601 women, 449 were low 
risk and 152 were high risk. There were 578 term 
deliveries (141 high risk and 437 low risk) and 23 
preterm deliveries (11 high risk and 12 low risk) in the 
primary analysis. Median gestational age of delivery in 
women who delivered preterm was 36 weeks (range 
34-36 weeks).
A  total of 13,347 samples were submitted. Thirty-one 
(0.23%) could not be analyzed because of insufficient 
saliva volume or tubes broken in mailing. The mean ( 
standard deviation [SD]) interval between samples was
1.1 ±  0.1 weeks for evaluable subjects.
Initially we validated the cut-off point of 2.1 ng/m L  
comparing ROC curves generated from women in the 
current study to curves from the pilot study. As shown 
in Figure 2, there was a slight decrease in overall test 
sensitivity in the current study, but a cutoff of 2.1 
ng/m L generated optimal sensitivity and specificity. If
T ab le  2. Numbers of Subjects for Primary Endpoints
Subjects Enrolled Analyzed
High risk 302 (31.5%) 152 (25.3%)
Low risk 654 (68.5%) 449 (74.7%)
Combined groups 956 601
Preterm births 37 weeks 121 (12.6%) 23 (3.8%)
Spontaneous preterm births 71 (7.4%) 23 (3.8%)
Preterm PROM 21 (2.2%) 0
Medically indicated 29 (3.0%) 0






Medically indicated preterm 10
births
Term with preterm labor 55
Subjects not eligible 242
PROM premature rupture of membranes.
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T ab le  4. Time Interval to Delivery in Women With a Single 
Positive or a Second Positive Test
Figure 2. Receiver operating characteristic analysis: maximum in­
trapatient salivary estriol value and its ability to predict preterm birth, 
considering values collected at 24-36 weeks' gestation (n = 601) in our 
feasibility study and the current study.
the cut-off point level of salivary E3 was lowered to 1.9 
ng/m L, sensitivity increased to 70%, but the false- 
positive rate increased from 22% to 34%. A  value of 1.6 
ng/m L detected 91% of women who delivered preterm 
with a false-positive rate of 54%. No women delivered 
prematurely below a value of 1.2, but the false-positive 
rate at that level was 88%.
As shown in Table 3, a salivary E3 level of at least 2.1 
ng/m L associated significantly with preterm birth in 
each group (P <  .05) with risk ratios ranging from 3.4 to 
4.2. In the low-risk population, a single positive salivary 
E3 test before 36 completed weeks' gestation was a 
significant risk indicator for preterm delivery (P = .018) 
identifying 50% (95% CI 21.1%, 78.9%) of the spontane­
ous preterm births. A  single positive test also identified 
64% (95% CI 30.8%, 89.1%) of women who delivered 
preterm in the high-risk group. In the combined popu­
lation, 57% (95% CI 34.5%, 76.8%) of women who had 
preterm deliveries had at least one elevated salivary E3 
test.




Second positive test 
(n = 10)
1 23.1% (5.0, 53.8) 70.0% (34.8,93.3)
2 53.9% (25.1, 80.8) 90.0% (55.5,99.8)
3 84.6% (54.6,98.1) 100.0% (69.2,100.0)
4 92.3% (64.0,99.8) 100.0% (69.2,100.0)
5 92.3% (64.0,99.8) 100.0% (69.2,100.0)
Data are given as % (95% confidence interval).
enhanced by a second positive test of new saliva sample 
collected 1 week after the first positive test (Table 4). 
The occurrence of spontaneous preterm labor and de­
livery in women with a second elevated E3 level was 
19%. Only 2% of women who had a salivary E3 below
2.1 ng/m L on the second test had spontaneous preterm 
labor and delivery. The number of women identified as 
at risk for preterm labor was reduced from 23.6% (142 
of 601, overall incidence of having a single positive test) 
to 9.0% (54 of 601, the incidence of having a positive 
second test). The incidence of preterm labor with deliv­
ery in women with two consecutive salivary E3 tests of 
at least 2.1 ng/m L compared with incidence of women 
with salivary E3 under 2.1 ng/m L was 14.2% versus 
1.7% in the low-risk population, 26.3% versus 4.5% in 
the high-risk population, and 18.5% versus 2.4% in the 
combined population.
Analyses were done to determine time to delivery 
from a positive test. Among eligible women, 22 had at 
least one positive salivary E3 test and delivered pre­
term. The median time to delivery in that group was 3.6 
weeks. Among women who were eligible for the pri­
mary analysis and had at least one positive salivary E3 
test, the median time to preterm birth was 2.3 weeks. 
Eighty-six percent of those women delivered in fewer 
than 3 weeks (Table 4). All women who had preterm 
births and a second positive test delivered in less than 3 
weeks.





predictive value Relative risk
Combined population
Single positive test* 57 (34.5, 76.8) 78 (74.1, 81.0) 9 (5.0,15.2) 98 (96.0,99.0) 4.2 (1.9, 9.4)
Second positive test* 44 (23.2, 65.5) 92 (89.9,94.4) 19 (9.3,31.4) 98 (96.0,98.7) 7.8 (3.6,16.9)
Low-risk population
Single positive test 50 (21.1, 78.9) 81 (76.8, 84.4) 7 (2.5,14.0) 98 (96.4,99.4) 4.0 (1.3,12.1)
Second positive test* 42 (15.2, 72.3) 93 (90.0,95.3) 14 (4.8,30.3) 98 (96.6,99.3) 8.5 (2.8, 25.2)
High risk population
Single positive test 64 (30.8, 89.1) 68 (59.7, 75.7) 14 (5.6, 25.8) 96 (90.1,98.9) 3.4 (1.0,11.0)
Second positive test* 46 (16.8, 76.7) 90 (83.9,94.5) 26 (9.2,51.2) 96 (90.4,98.3) 5.8 (2.0,17.3)
Data are given as % (95% confidence interval). 
* P <  .05. 
f P <  .005.
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Figure 3. Survival analysis for subjects with single positive salivary 
estriol (sE3) (at or below 2.1 ng/m L) at under 28 weeks' gestation 
compared with all subjects.
Survival analysis that represented time from a single 
positive or negative test at a specific gestational age to 
delivery was done on the entire population (n =  714), 
including preterm deliveries treated with betametha­
sone or tocolytics, PROM, and medically indicated 
preterm births. Survival analysis found significant 
shortening of gestation in women with a single positive 
test at under 28 weeks' (Figure 3), 32 weeks', or 34 
weeks' gestation (data not shown) compared with all 
subjects (P <  .05).
Among the 714 subjects, 158 presented with signs or 
symptoms of preterm labor. Of those, 115 met criteria 
for preterm labor diagnosis. The remaining 43 were 
evaluated for preterm contractions. The incidence val­
ues for symptomatic women were done on an intent- 
to-treat basis. The average time to delivery was 5.4 ±  4.9 
weeks after presentation. Delivery within 2 weeks oc­
curred in 35% of subjects. The mean ±SD salivary E3 
value within 1 week before admission was 1.95 1.44 
ng/m L in those who delivered within 2 weeks versus 
1.16 ±  .60 ng/m L in those who did not (P <  .001). Two 
weeks before admission the values were 1.85 ±  1.40 and 
1.18 ±  0.57 ng/m L, respectively (P =  .001). Receiver 
operating characteristic curves to determine the ideal 
threshold of salivary E3 to determine the risk of preterm 
delivery are presented in Figure 4. A  salivary E3 level of 
at least 2.1 ng/m L identified 29.4% of deliveries within
2 weeks with a false-positive rate of 7.8%. The ideal 
salivary E3 threshold appeared to be 1.4 ng/m L, which 
had a sensitivity of 61% and a specificity of 76%.
Discussion
In this prospective trial, incidence of preterm labor and 
delivery was greater in women who had at least one 
salivary E3 value of 2.1 ng/m L or greater on longitudi­
nally collected salivary samples, which supports an
Figure 4. Estriol value collected no more than 1 week before initial 
hospital admission. Positive result defined as delivery at or less than 2 
weeks from the date of admission.
established threshold value. Regardless of a woman's 
risk classification, the risk of preterm birth was substan­
tially higher in women with at least one elevated 
salivary E3 test. Reduction of the threshold value sig­
nificantly enhanced the sensitivity of the test (Figure 3), 
but the false-positive rate increased.
The ability to determine preterm birth in the single 
positive test group was offset by the low positive 
predictive values of 7-14%. Two consecutive, elevated 
salivary E3 levels improved the predictive accuracy of 
the test. In both study groups, the RR for preterm birth 
approximately doubled. Specificity and positive predic­
tive value improved with a positive second test, with 
only slight diminution in test sensitivity. The negative 
predictive value for preterm birth after spontaneous 
preterm labor for single and second positive tests was 
98%, which means that it is highly unlikely that preterm 
labor and delivery will occur in women with low 
salivary E3 values.
Among our population, 22% of women presented 
with symptoms of preterm labor. Most of those women 
delivered more than 5 weeks after presentation. Among 
women who delivered within 2 weeks of presentation, 
salivary E3 values were significantly higher at 1 and 2 
weeks before admission. At our threshold of 2.1 ng/m L, 
salivary E3 identified only 29% of those who delivered 
within 2 weeks. That increased to 61% when the thresh­
old salivary E3 value was decreased to 1.4 ng/m L, but 
specificity decreased from 92% to 76%.
Salivary E3 testing was similarly accurate in predict­
ing preterm birth in low- and high-risk groups. Salivary 
E3 testing was accurate in primiparous women and 
those with no recognized risk factor. Strengths of this 
trial included the large number of subjects in geograph­
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ically diverse populations and the masking. Weak­
nesses included the relatively few preterm births de­
spite many enrollees, as a consequence of our stringent 
criteria, which excluded women with multiple gesta­
tions, PROM, and those treated with corticosteroids and 
tocolytics, except in the survival analysis and in our 
symptomatic patient analysis. Such exclusion criteria 
were designed to increase internal validity but might 
reduce external validity, ie, applicability to other 
groups of women.
A  further limitation of the study was lack of experi­
ence with very early preterm births (ie, before 30 weeks' 
gestation). In this trial, all the E3-positive preterm births 
were after 32 weeks' gestation. This finding is not 
surprising because 80% of preterm births occur between 
34 and 36 weeks. Most of our subjects who delivered at 
earlier gestations were evaluated for symptoms of pre­
mature labor but delivered on average more than 5 
weeks after the initial event. Almost all received beta­
methasone at initial presentation, which suppresses E3 
production, and tocolytics, which have unknown ef­
fects, making levels of E3 after initial presentation 
difficult to interpret.
Infection accounts for approximately 30% of preterm 
births at less than 32 weeks.20,21 Estriol might not 
identify infection-mediated preterm birth at earlier ges­
tations but theoretically would identify women with 
idiopathic preterm labor. Survival analysis, which 
found a shortening of gestational age if E3 was positive 
at less than 28, 32, or 34 weeks' gestation, supports that 
concept. The ability of salivary E3, albeit at a lower 
threshold of 1.4 ng/m L, to predict most but not all 
women who will deliver with symptoms of preterm 
labor, provides further support.
Potential explanations of the lower salivary E3 
threshold required to identify symptomatic women 
who then deliver include time of collection relative to 
delivery and gestational age at collection. The salivary 
E3 specimens collected 1 to 2 weeks before preterm 
labor symptoms were up to 3 to 4 weeks from actual 
delivery and might represent initiation of the salivary 
E3 surge, which would have continued had treatment 
not been initiated. There also was a slight increase in 
salivary E3 normally seen with advancing gestation that 
suggests a lower threshold might be necessary at the 
earlier gestational ages at which those women 
presented.
Salivary E3 testing offers several advantages as a 
risk-assessment marker for preterm labor. Testing for 
elevated levels of salivary E3 (at least 2.1 ng/mL) is 
simple, convenient, and noninvasive. Samples can be 
collected at home or in the clinic. Serial salivary E3 
determinations can also be easily integrated into com­
mon pregnancy management protocols. Physical signs
and symptoms of preterm labor can be subtle, but if 
they escape recognition, the opportunity for early treat­
ment might be missed.9,22,23 Use of an objective bio­
chemical test, such as salivary E3, can aid early detec­
tion of preterm labor before physical symptoms are 
manifest. Threshold levels of salivary E3 were achieved 
approximately 3 weeks before parturition, so there 
might be time to evaluate previously unproved inter­
ventions, such as decreased maternal activity or admin­
istration of prophylactic tocolytics, which might im­
prove pregnancy outcomes.
Salivary E3 is a noninvasive biologic marker that can 
be used to assess risk for spontaneous preterm labor 
and delivery in asymptomatic and symptomatic 
women. Serial salivary E3 testing can improve accuracy 
in assessment of risk of preterm birth, especially in 
women at high risk of preterm labor and delivery using 
traditional scoring methods. Unproved interventions, 
such as weekly office visits with serial cervical exami­
nations and discontinuation of work and family respon­
sibilities, can be avoided with most women previously 
deemed at high risk. Future studies to evaluate poten­
tial treatments of women with elevated salivary E3 are 
required before its use can be recommended in the 
general low-risk obstetric population.
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